clinical trial

Nexalin's DIFS neurostimulation technology reduced self-injury and depression symptoms in female adolescents, per peer-reviewed study published in BMC Psychiatry.

Trogenix publishes Nature data showing 83% complete tumor elimination in aggressive brain cancer model. Phase I/II trial dosing planned for Q2 2026.

Incyclix Bio raises $5M from Hatteras Venture Partners for Phase 1/2 trial of INX-315, targeting therapy-resistant breast and ovarian cancers.

Class action lawsuit filed against $SLNO for allegedly concealing safety concerns and patient death related to experimental drug DCCR, causing significant shareholder losses.

Soleno Therapeutics faces class action lawsuit alleging failure to disclose material DCCR drug safety concerns, including excess fluid retention in clinical trials that reduced commercial viability.

Investors in $REGENXBIO face class action lawsuit alleging false statements about RGX-111 gene therapy development and clinical trial results spanning 2022-2026.

Geron Corporation will discuss its commercial-stage telomerase inhibitor platform at the Needham Healthcare Conference on April 13, highlighting RYTELO® adoption and ongoing Phase 3 trials in myelofibrosis.

Praxis reports 77% placebo-adjusted seizure reduction in SCN2A epilepsy treatment with no serious safety events, advancing precision neurotherapy.

Soligenix's HyBryte demonstrated superior efficacy versus Valchlor in treating cutaneous T-cell lymphoma, with 60% versus 20% success rates at 12 weeks, backed by $2.6M FDA grant.

Immunovant's batoclimab failed to meet primary efficacy targets in Phase 3 thyroid eye disease trials, though safety remained consistent. Company pivots focus to Graves' disease studies.

Adagene reports 29% response rate for ADG126 in colorectal cancer with improved safety profile. Company maintains $74.5M cash reserves extending runway into early 2028.

AskBio completes enrollment of 173 patients in Phase 2 trial for AB-1002 gene therapy targeting heart failure. Results expected H1 2027.

FibroBiologics prices $3M offering and validates manufacturing of CYWC628 for diabetic ulcer trials while restoring Nasdaq compliance.

BrainStorm Cell Therapeutics reported $10.3M net loss for 2025 while securing $2M financing and advancing NurOwn into Phase 3b ALS study following FDA clearance.

Boston Scientific shares fell 9% after Watchman FLX trial met all endpoints but disappointed investors seeking transformative clinical data to accelerate growth.

BridgeBio reports acoramidis cuts all-cause mortality 44.7% and cardiovascular mortality 49.3% in ATTR-CM patients at Month 54 versus placebo.

Class action lawsuit filed against $SLNO alleging fraud over PWS drug DCCR. Safety concerns, patient death, and commercial disruption emerged in 2025.

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.

Quantum BioPharma grants 35,000 stock options to employees at CA$6.50 strike, vesting immediately with five-year exercise window.

Novo Nordisk wins FDA approval for Awiqli, the first once-weekly basal insulin for Type 2 diabetes, potentially improving patient adherence and capturing significant market share.